Treatment Information

Back

Lung Cancer treatment details. Biologic therapy.

National Cancer Center, Goyang, Korea.

Survival: monthsCountry:Korea
Toxiciy Grade:5City/State/Province:Goyang
Treatments:Biologic therapyHospital:National Cancer Center
Drugs:Journal:Link
Date:Apr 2012

Description:

Patients:
This phase 3 study involved 617 previously treated advanced non-small-cell lung cancer patients.. The median patient age was 60 years and 47% were male.

Treatment:
Patients were treated with the biologic therapy agent vandetanib, which is a VEGF inhibitor that interferes with tumor blood supply.

Toxicities:
Treatment-related deaths were reported, with causes including respiratory problems. Grade 3 or higher diarrhea, rash, and high blood pressure were also reported.

Results:
The median overall survival was 8.5 months.

Support:
This study was supported by the pharmaceutical company AstraZeneca.

Correspondence: Dr. Jin Soo Lee; email: [email protected]



Back